[go: up one dir, main page]

WO2012015691A3 - Recombinant lectins, binding-site modified lectins and uses thereof - Google Patents

Recombinant lectins, binding-site modified lectins and uses thereof Download PDF

Info

Publication number
WO2012015691A3
WO2012015691A3 PCT/US2011/044989 US2011044989W WO2012015691A3 WO 2012015691 A3 WO2012015691 A3 WO 2012015691A3 US 2011044989 W US2011044989 W US 2011044989W WO 2012015691 A3 WO2012015691 A3 WO 2012015691A3
Authority
WO
WIPO (PCT)
Prior art keywords
lectins
binding
glucose
conjugates
binding sites
Prior art date
Application number
PCT/US2011/044989
Other languages
French (fr)
Other versions
WO2012015691A2 (en
Inventor
Thomas M. Lancaster
Robert Butters
Naomi R. Choodnovskiy
Todd C. Zion
Original Assignee
Smartcells, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smartcells, Inc. filed Critical Smartcells, Inc.
Priority to CA2805902A priority Critical patent/CA2805902A1/en
Priority to US13/811,981 priority patent/US9068013B2/en
Priority to AU2011282987A priority patent/AU2011282987A1/en
Priority to JP2013521846A priority patent/JP2013541500A/en
Priority to EP11812983.2A priority patent/EP2598522A4/en
Publication of WO2012015691A2 publication Critical patent/WO2012015691A2/en
Publication of WO2012015691A3 publication Critical patent/WO2012015691A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

In one aspect, the disclosure provides cross-linked materials that include multivalent lectins with at least two binding sites for glucose, wherein the lectins include at least one affinity ligand which is capable of competing with glucose for binding with at least one of said binding sites and is covalently linked to a cysteine residue of the lectins; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with glucose for binding with the lectins at said binding sites and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between lectins and affinity ligands on different conjugates. These materials are designed to release amounts of conjugate in response to desired concentrations of glucose. Depending on the end application, in various embodiments, the conjugates may also include a drug and/or a detectable label.
PCT/US2011/044989 2010-07-28 2011-07-22 Recombinant lectins, binding-site modified lectins and uses thereof WO2012015691A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2805902A CA2805902A1 (en) 2010-07-28 2011-07-22 Recombinant lectins, binding-site modified lectins and uses thereof
US13/811,981 US9068013B2 (en) 2010-07-28 2011-07-22 Recombinant lectins, binding-site modified lectins and uses thereof
AU2011282987A AU2011282987A1 (en) 2010-07-28 2011-07-22 Recombinant lectins, binding-site modified lectins and uses thereof
JP2013521846A JP2013541500A (en) 2010-07-28 2011-07-22 Recombinant lectins, binding site modified lectins and their uses
EP11812983.2A EP2598522A4 (en) 2010-07-28 2011-07-22 Recombinant lectins, binding-site modified lectins and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36860210P 2010-07-28 2010-07-28
US61/368,602 2010-07-28

Publications (2)

Publication Number Publication Date
WO2012015691A2 WO2012015691A2 (en) 2012-02-02
WO2012015691A3 true WO2012015691A3 (en) 2013-08-08

Family

ID=45530662

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/044989 WO2012015691A2 (en) 2010-07-28 2011-07-22 Recombinant lectins, binding-site modified lectins and uses thereof

Country Status (6)

Country Link
US (1) US9068013B2 (en)
EP (1) EP2598522A4 (en)
JP (1) JP2013541500A (en)
AU (1) AU2011282987A1 (en)
CA (1) CA2805902A1 (en)
WO (1) WO2012015691A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9427475B2 (en) 2013-10-04 2016-08-30 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1007457A2 (en) 2009-01-28 2015-08-25 Smartcells Inc Conjugate, extended release formulation, and pump distribution system.
US20140350370A1 (en) * 2013-04-08 2014-11-27 The Texas A&M University System Glucose sensing assay
KR20180038049A (en) 2015-08-25 2018-04-13 노보 노르디스크 에이/에스 Novel Insulin Derivatives and Their Medical Use
CA3159114A1 (en) 2019-12-11 2021-06-17 Frantisek Hubalek Novel insulin analogues and uses thereof
CN116496331A (en) * 2022-01-18 2023-07-28 中国科学院上海药物研究所 Amygdalin derivative, specific modified product obtained from amygdalin derivative and preparation method of amygdalin derivative
CN115215927B (en) * 2022-07-18 2025-07-29 杭州纽龙生物科技有限公司 Streptavidin containing long-chain sulfhydryl arm and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099820A1 (en) * 2005-10-19 2007-05-03 Smartcells, Inc. Polymer-drug conjugates
US20070207498A1 (en) * 2005-02-24 2007-09-06 Lifescan, Inc. Design and construction of dimeric concanavalin a mutants

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591574A (en) 1968-05-29 1971-07-06 American Home Prod Tri-n-phenylglycyl derivatives of insulin
DE1793517C3 (en) 1968-09-28 1974-12-05 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt N (Al), N (B29> bis (tert-butyloxycarbonyl) insulin and process for its preparation
US3847890A (en) 1971-11-01 1974-11-12 A Green Acidic monosaccharide-substituted proteins
US4377567A (en) 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
DE2964024D1 (en) 1978-10-02 1982-12-16 Procter & Gamble Liposomes for drug delivery and composition containing a liposome drug system
US4348387A (en) 1979-07-31 1982-09-07 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
JPS608000B2 (en) 1980-04-11 1985-02-28 呉羽化学工業株式会社 Aminophenyl derivatives and bioactive agents containing the derivatives
US4444683A (en) 1982-11-17 1984-04-24 University Of Utah Glycosylated insulin derivatives
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
EP0119650A3 (en) 1983-03-21 1987-09-30 THE PROCTER & GAMBLE COMPANY Galactosyl-insulin conjugates useful in treating diabetics
US4863896A (en) 1984-05-03 1989-09-05 Technology Unlimited, Inc. Diabetic control by combined insulin forms
US5395924A (en) 1986-03-20 1995-03-07 Dana-Farber Cancer Institute, Inc. Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
US5239062A (en) 1986-03-20 1993-08-24 Dana-Farber Cancer Institute, Inc. Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity
US5527524A (en) 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
DK111489D0 (en) 1989-03-08 1989-03-08 Novo Nordisk As PEPTIDES
AU628674B2 (en) 1989-10-19 1992-09-17 Nippon Oil And Fats Company, Limited Polymer complexes of a sugar response type
GB9200638D0 (en) 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
WO1993016176A1 (en) 1992-02-13 1993-08-19 Bio-Metric Systems, Inc. Immobilization of chemical species in crosslinked matrices
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
GB9313484D0 (en) 1993-06-30 1993-08-11 Univ Montfort Drug system ii
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
TW520293B (en) 1995-11-22 2003-02-11 Univ Johns Hopkins Med Delivery system to enhance cellular uptake of biomolecules
US5723589A (en) 1995-12-21 1998-03-03 Icn Pharmaceuticals Carbohydrate conjugated bio-active compounds
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
JP2001527387A (en) 1997-01-24 2001-12-25 ノボ ノルディスク アクティーゼルスカブ Synthetic leader peptide sequence
AR012894A1 (en) 1997-06-13 2000-11-22 Lilly Co Eli FORMULATION OF INSULIN IN STABLE SOLUTION, ITS USE TO PREPARE A MEDICINAL PRODUCT AND PROCESS FOR THE PREPARATION OF THE SAME.
ATE299889T1 (en) 1998-04-15 2005-08-15 Novo Nordisk As NEW METHOD FOR SEPARATING PROTEINS USING AN ELUTION AGENT CONTAINING CA++
US6844166B1 (en) 1998-09-11 2005-01-18 Sensor Technologies Inc. Recombinant reduced valency carbohydrate binding ligands
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US6777207B2 (en) 1999-12-29 2004-08-17 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast
US6521738B2 (en) 1999-12-29 2003-02-18 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogs
JP2003535106A (en) 2000-06-02 2003-11-25 ノボ ノルディスク アクティーゼルスカブ Glucose-dependent release of insulin from glucose-sensitive insulin derivatives
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US20020192182A1 (en) 2001-03-12 2002-12-19 Stephen Massia Polysaccharide-based polymerizable hydrogels
US7105314B2 (en) 2001-04-02 2006-09-12 Novo Nordisk A/S Method for making human insulin precursors
US7311892B2 (en) 2001-10-26 2007-12-25 The Uab Research Foundation Multidrug multiligand conjugates for targeted drug delivery
US7317000B2 (en) 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
JP3869828B2 (en) 2001-12-07 2007-01-17 株式会社エヌ・ティ・ティ・ドコモ Mobile communication terminal, application program execution state control method, application program, and recording medium recording application program
DE10209821A1 (en) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of proteins to a modified polysaccharide
CA2493674A1 (en) 2002-07-19 2004-01-29 The Regents Of The University Of California Dendrimers as molecular translocators
US7531191B2 (en) 2002-12-17 2009-05-12 Massachusetts Institute Of Technology Stimuli-responsive systems for controlled drug delivery
AU2003294912B2 (en) 2002-12-20 2009-06-04 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
US20080102114A1 (en) 2004-04-23 2008-05-01 Panduranga Rao Koritala Microparticles and Nanoparticles for the Transmucosal Delivery of Therapeutic and Diagnostic Agents
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
ES2535823T3 (en) 2004-07-19 2015-05-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses of these
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
US20060247154A1 (en) 2005-02-24 2006-11-02 Lifescan, Inc. Concanavalin a, methods of expressing, purifying and characterizing concanavalina, and sensors including the same
WO2006102762A1 (en) 2005-04-01 2006-10-05 Mcmaster University Glucose responsive microgels
AU2006301240A1 (en) 2005-10-10 2007-04-19 Msd Oss B.V. Antithrombotic compound
US7517856B2 (en) 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
EP1991576B1 (en) 2006-02-27 2010-09-29 Novo Nordisk A/S Insulin derivatives
EP2043689A4 (en) 2006-07-24 2013-08-07 Univ Duke DRUG ADMINISTRATION WITH STIMULI-SENSITIVE BIOPOLYMERS
DE602007006492D1 (en) 2006-07-25 2010-06-24 Lipoxen Technologies Ltd DERIVATISATION OF THE GRANULOCYTE COLONIESTIMULATING FACTOR
FR2904315B1 (en) 2006-07-26 2012-12-14 Centre Nat Rech Scient PYRIDAZINIC AND PYRROLIC COMPOUNDS, METHODS OF OBTAINING AND APPLICATIONS
CN101273961A (en) 2007-03-30 2008-10-01 中国人民解放军总医院 glucose sensitive hydrogel
US20090053167A1 (en) 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
WO2009033588A2 (en) 2007-09-11 2009-03-19 F. Hoffmann-La-Roche Ag Self-controlled insulin delivery system
WO2009059450A1 (en) 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
EP2242505A4 (en) 2008-01-08 2012-03-07 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
RU2381238C2 (en) 2008-01-31 2010-02-10 Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (статус государственного учреждения) Method of preparing glucose-sensitive polymer hydrogels
CN102015762B (en) 2008-02-19 2015-03-18 百康有限公司 Method for obtaining purified biologically active heterologous proteins
EP2391216A4 (en) 2009-01-28 2013-06-19 Smartcells Inc Exogenously triggered controlled release materials and uses thereof
JP2012516156A (en) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド Polynucleotide aptamer-based cross-linked substance and use thereof
WO2010088261A1 (en) * 2009-01-28 2010-08-05 Smartcells, Inc. Binding-site modified lectins and uses thereof
EP2391217A4 (en) 2009-01-28 2015-05-20 Smartcells Inc Synthetic conjugates and uses thereof
BRPI1007457A2 (en) 2009-01-28 2015-08-25 Smartcells Inc Conjugate, extended release formulation, and pump distribution system.
PE20120582A1 (en) 2009-01-28 2012-05-26 Smartcells Inc CRYSTALLINE INSULIN CONJUGATES
WO2011000823A1 (en) 2009-06-30 2011-01-06 Novo Nordisk A/S Insulin derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207498A1 (en) * 2005-02-24 2007-09-06 Lifescan, Inc. Design and construction of dimeric concanavalin a mutants
US20070099820A1 (en) * 2005-10-19 2007-05-03 Smartcells, Inc. Polymer-drug conjugates

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEPPU ET AL.: "Covalently cross-linked monovalent, divalent, and tetravalent derivatives of concanavalin A.", J BIOCHEM, vol. 85, 1979, pages 1275 - 1287, XP055114113 *
HIRABAYASH ET AL.: "Effect of amino acid substitution by site-directed mutagnesis on the carbohydrate recognition and stability of human 14-kDa beta-galactoside-binding lectin.", J BIOL CHEM, vol. 266, 1991, pages 23648 - 23653, XP055114116 *
LINDHORST ET AL.: "Trivalent alpha-D-mannoside clusters as inhibitors of type-1 fimbriae-mediated adhesion of Escherichia coli: structural variation and biotinylation.", J CHEM SOC PERKIN TRANS, vol. 1, 2001, pages 823 - 831, XP002554820 *
See also references of EP2598522A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9427475B2 (en) 2013-10-04 2016-08-30 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates

Also Published As

Publication number Publication date
WO2012015691A2 (en) 2012-02-02
EP2598522A2 (en) 2013-06-05
US20130324702A1 (en) 2013-12-05
AU2011282987A1 (en) 2013-02-21
JP2013541500A (en) 2013-11-14
CA2805902A1 (en) 2012-02-02
EP2598522A4 (en) 2014-11-12
US9068013B2 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
WO2012015691A3 (en) Recombinant lectins, binding-site modified lectins and uses thereof
WO2010088276A3 (en) Polynucleotide aptamer-based cross -linked materials and uses thereof
EP2408470A4 (en) Soluble non-depot insulin conjugates and uses thereof
IL283205A (en) Cell binding agent drug conjugates, compositions comprising the same and uses thereof
JP2012062311A5 (en)
IL219268A (en) Anti-cd79b antibody, immunoconjugate and pharmaceutical composition comprising it and uses thereof
WO2011069104A3 (en) Multispecific antibodies, antibody analogs, compositions, and methods
BR112012013975A2 (en) b7h6 binding monoclonal antibodies and uses thereof
WO2007095338A3 (en) Functional antibodies
IL221205A0 (en) Antibody drug conjugates (adc) that bind to 161p2f10b proteins, compositions comprising the same and uses thereof
WO2013093720A3 (en) Anti-diabetic compounds
WO2007106744A3 (en) Anti-5t4 antibodies and uses thereof
WO2008003103A3 (en) Novel multivalent immunoglobulins
WO2014059442A8 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
IL211284A0 (en) Antibodies binding ccr2, compositions comprising the same and uses thereof
EP3029066A3 (en) Antibodies with modified isoelectric points
WO2013158454A3 (en) Compounds and methods for preparation of conjugate reagents
NZ595344A (en) Drug fusions and conjugates
IL219653A0 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
EP2490720A4 (en) ANTI-GCC ANTIBODY MOLECULES, COMPOSITIONS AND RELATED METHODS
SI2403605T1 (en) Compositions comprising an aP2-specific antibody or a fragment thereof for use in treating diabetes, glucose intolerance or obesity-induced insulin resistance
GB201015040D0 (en) Novel antigen binding dimer complexes, methods of making and uses thereof
WO2009094561A8 (en) Induced internalization of surface receptors
WO2008137552A3 (en) Anti-rage antibodies and methods of use thereof
WO2011053565A3 (en) Compositions and methods for detecting a tauopathy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11812983

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2805902

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013521846

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13811981

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2011282987

Country of ref document: AU

Date of ref document: 20110722

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2011812983

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011812983

Country of ref document: EP